NCT07025369View on ClinicalTrials.gov

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 25, 2025

Primary Completion Date

July 27, 2026

Study Completion Date

July 27, 2026

Conditions
Prostate AdenocarcinomaStage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo PET/CT

OTHER

Flotufolastat F-18 Gallium

Given flotufolastat F 18

PROCEDURE

Laparoscopic Radical Prostatectomy with Robotics

Undergo robotic assisted radical prostatectomy

PROCEDURE

Pelvic Lymphadenectomy

Undergo pelvic lymph node dissection

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

DRUG

Relugolix

Given PO

Trial Locations (1)

85259

RECRUITING

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT07025369 - Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial | Biotech Hunter | Biotech Hunter